中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 9
Sep.  2024
Turn off MathJax
Article Contents

The therapeutic paradigm of liver surgery in the era of conversion therapy

DOI: 10.12449/JCH240901
  • Received Date: 2024-08-31
  • Accepted Date: 2024-09-06
  • Published Date: 2024-09-25
  • Surgical resection remains the best approach for achieving long-term survival in patients with hepatocellular carcinoma (HCC); however, due to the low early diagnosis rate of HCC patients in China, only 15%-20% of the patients are eligible for surgical resection at the time of initial diagnosis. Even for the patients undergoing surgery, the 5-year recurrence rate after surgery is as high as 50%-70%, resulting in an unsatisfactory prognosis. In recent years, the advances in systemic therapies, especially targeted therapy combined with immunotherapy, have not only extended the survival of patients with advanced liver cancer, but also promoted the application of systemic therapy in the earlier stages of HCC. On the one hand, the progress in systemic therapy has made conversion therapy a possible option for HCC, allowing a substantial number of patients with unresectable HCC at initial diagnosis to get the opportunity for surgical resection after downstaging and achieve a survival rate similar to those with resectable early-stage HCC at initial diagnosis; on the other hand, effective systemic therapy is being applied as neoadjuvant and adjuvant therapies for patients with resectable HCC, aiming to increase the R0 resection rate, reduce postoperative recurrence, and improve overall survival. Meanwhile, it should be clearly noted that although the advances in systemic therapy have significantly altered conventional surgical treatment paradigms, most clinical studies on conversion therapy, neoadjuvant therapy, and adjuvant therapy are small-scale phase II trials, with limited high-grade evidence from evidence-based medicine. It is important to select a reasonable therapeutic goal and develop an individualized treatment regimen based on the characteristics of tumor, and further explorations are needed to search for new biomarkers for predicting the efficacy of conversion therapy and perioperative treatment and identify the population with true benefits.

     

  • loading
  • [1]
    HAN BF, ZHENG RS, ZENG HM, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4( 1): 47- 53. DOI: 10.1016/j.jncc.2024.01.006.
    [2]
    ZHANG BH, DONG W, LUO HP, et al. Surgical treatment of hepato-pancreato-biliary disease in China: The Tongji experience[J]. Sci China Life Sci, 2016, 59( 10): 995- 1005. DOI: 10.1007/s11427-016-5104-8.
    [3]
    LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359( 4): 378- 390. DOI: 10.1056/NEJMoa0708857.
    [4]
    CHENG AL, KANG YK, CHEN ZD, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10( 1): 25- 34. DOI: 10.1016/S1470-2045(08)70285-7.
    [5]
    CHENG AL, QIN S, IKEDA M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76( 4): 862- 873. DOI: 10.1016/j.jhep.2021.11.030.
    [6]
    LENCIONI R, KUDO M, ERINJERI J, et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization[J]. J Clin Oncol, 2024, 42( 3_suppl): LBA432. DOI: 10.1200/jco.2024.42.3_suppl.lba432.
    [7]
    ZHAO HT, SANG XT, RUI JA, et al. Analysis of curative effect of unresectable advanced liver cancer resection after descending stage[J]. Acta Acad Med Sin, 2009, 31( 4): 503- 505. DOI: 10.3881/j.issn.1000-503X.2009.04.024.

    赵海涛, 桑新亭, 芮静安, 等. 不能手术切除的晚期肝癌降期后切除疗效分析[J]. 中国医学科学院学报, 2009, 31( 4): 503- 505. DOI: 10.3881/j.issn.1000-503X.2009.04.024.
    [8]
    YU YQ, TANG ZY, ZHOU XD, et al. Treatment of large hepatocellular carcinoma by stages[J]. Chin J Surg, 1983, 21( 2): 92- 93.

    余业勤, 汤钊猷, 周信达, 等. 大肝癌的分阶段治疗[J]. 中华外科杂志, 1983, 21( 2): 92- 93.
    [9]
    CHEN H, WU MC, ZHANG XH. Two-stage resection of primary liver cancer: a report of 9 cases[J]. J Pract Surg, 1988, 8( 10): 529- 530.

    陈汉, 吴孟超, 张晓华. 二期手术切除原发性肝癌九例报告[J]. 实用外科杂志, 1988, 8( 10): 529- 530.
    [10]
    National Health Commission of the People's Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
    [11]
    WANG Z, REN ZG, CHEN Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: A randomized controlled study[J]. Clin Cancer Res, 2018, 24( 9): 2074- 2081. DOI: 10.1158/1078-0432.CCR-17-2899.
    [12]
    WEI W, JIAN PE, LI SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: A randomized clinical trial of efficacy and safety[J]. Cancer Commun, 2018, 38( 1): 61. DOI: 10.1186/s40880-018-0331-y.
    [13]
    QIN SK, CHEN MS, CHENG AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma(IMbrave050): A randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023, 402( 10415): 1835- 1847. DOI: 10.1016/S0140-6736(23)01796-8.
    [14]
    LI BK, WANG CW, HE W, et al. Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: A propensity score-matching comparative study[J]. Int J Surg, 2024, 110( 5): 2545- 2555. DOI: 10.1097/JS9.0000000000001155.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (211) PDF downloads(70) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return